Search clinical trials for: Regorafenib (Stivarga, BAY 73-4506)

Total 396 results

Bayer

Completed

Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy (RECORA)

Colorectal Neoplasm

Germany
Northwestern University
National Cancer Institute (NCI); Bayer

Completed

Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Angiosarcoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Pulmonary Carcinoid Tumor

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment

Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal Adenocarcinoma

United States
Great Novel Therapeutics Biotech & Medicals Corporation

Recruiting

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

Taiwan
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Terminated

Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery

Adenocarcinoma of the Gastroesophageal Junction | Stage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma | Stage IIB Esophageal Adenocarcinoma

United States
US Oncology Research
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Terminated

Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

Colorectal Neoplasms | Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

United States
AHS Cancer Control Alberta
Cross Cancer Institute

Withdrawn

Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients

Metastatic Solid Malignancies | Locally Advanced Solid Malignancies

Canada
CStone Pharmaceuticals
Bayer

Completed

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

Advanced Refractory Solid Tumors

Australia
M.D. Anderson Cancer Center
Bayer; Xencor, Inc.

Withdrawn

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

Colorectal Cancer | Colon Cancer | Rectum Cancer

United States
Memorial Sloan Kettering Cancer Center
Bayer; State University of New York - Downstate Medical Center; Queens Cancer...

Active, not recruiting

Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma

Metastatic Colorectal Adenocarcinoma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma

United States
National Taiwan University Hospital
National Taiwan University Hospital, Yun-Lin Branch

Recruiting

Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Taiwan
Gerald Batist
Bayer; Quebec Clinical Research Organization in Cancer

Unknown

Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers

Metastatic Colorectal Cancer

Canada
Bayer

Completed

Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy (REGARD)

Colorectal Neoplasms

Turkey
Bayer

Completed

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Neoplasms

Canada, United States
Bayer

Completed

Regorafenib Phase I Study in Mainland Chinese Patients

Oncology

China
Bayer

Completed

Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors

Neoplasms

Hong Kong, Singapore
Bayer

Completed

Stivarga Regulatory Post-Marketing Surveillance Study in Korea (StivargaPMS)

Colorectal Neoplasms

Korea, Republic of
Bayer

Completed

Regorafenib Post-marketing Surveillance in Japan

Gastrointestinal Stromal Tumors

Japan
Bayer

Completed

Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer (REGO-ACT)

Colorectal Neoplasms

Austria
Bayer

Completed

Stivarga Real Life Evidence in Hungary

Colorectal Neoplasms

Hungary
Bayer

Completed

The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib

Pharmacokinetics | Dietary Fats

United States
Ibrahim Halil Sahin
Bayer

Not yet recruiting

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

MSI-H Colorectal Cancer

United States
Bayer

Completed

Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

Metastatic Colorectal Cancer

India
Bayer

Completed

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Neoplasm

United States
Bayer

Not yet recruiting

An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States

Advanced Gastrointestinal Stromal Tumor

United States
Bayer

Recruiting

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Solid Malignant Tumors

Taiwan, Japan, Korea, Republic of, France, India, Spain
Bayer

Completed

An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States (COLONGER)

Metastatic Colorectal Cancer

United States
Bayer

Completed

A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC

Carcinoma, Renal Cell

United States, France, United Kingdom, Finland, Germany, Poland
Bayer

Completed

Regorafenib Post-marketing Surveillance

Colorectal Neoplasms

Japan
Bayer

Completed

Safety and Effectiveness of Regorafenib (Correlate)

Neoplasms

Austria, Czechia, Switzerland, Italy, France, Mexico, Singapore, Luxembourg, Netherlands, Spain, Taiwan, Denmark, Argentina
Bayer

Completed

Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity

Neoplasms

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer

Colorectal Cancer | Colorectal Cancer Metastatic

United States
Bayer

Completed

Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib (COLONG)

Colorectal Neoplasms

Belgium
Bayer

Terminated

A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes? (SMART)

Physician Education

United States
Bayer

Terminated

Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer

Neoplasms

United States
Bayer

Completed

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

Liver Neoplasms

United States, Canada, Japan, Spain, Sweden, Belgium, Argentina, Austria, Greece, Italy, Korea, Republic of, Netherlands, Russian Federation, Taiwan, Turkey, China, Denmark, Egypt, France, Saudi Arabia, Thailand
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

Cancer of the Bile Duct

United States
Peking Union Medical College Hospital

Recruiting

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Regorafenib

China
Institute of Mother and Child, Warsaw, Poland
Maria Sklodowska-Curie National Research Institute of Oncology

Recruiting

Regorafenib in Patients With Refractory Primary Bone Tumors (Regbone)

Osteosarcoma | Ewing Sarcoma of Bone

Poland
Massachusetts General Hospital
Bayer

Completed

Study of Regorafenib in Patients With Advanced Myeloid Malignancies

Acute Myeloid Leukemia

United States
Grupo Espanol de Investigacion en Sarcomas
Bayer

Completed

Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)

Gastrointestinal Stromal Tumors

Spain, France, Italy
Bayer

Completed

Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE)

Carcinoma, Hepatocellular

France, Spain, China, Switzerland, United States, Singapore, Germany, Russian Federation, Taiwan, Austria, Czechia, United Kingdom, Korea, Republic of, Australia, Hungary, Italy, Netherlands, Japan, Belgium, Brazil, Argentina
Dana-Farber Cancer Institute
Bayer

Active, not recruiting

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

Thyroid Cancer

United States
Istituto Clinico Humanitas

Completed

Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy (RESOUND)

Melanoma | Sarcoma | Ovarian Cancer | Thymic Carcinoma | Pancreas Cancer | Thymoma Type B3 | Thymoma Type B2

Italy
University of Rochester
Bayer

Completed

Regorafenib in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Chang Gung Memorial Hospital

Completed

Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation

Gastrointestinal Stromal Tumour (GIST)

Taiwan
Nathan Bahary, MD
Bayer

Completed

A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy

Metastatic Biliary Tract Carcinoma

United States
Asan Medical Center

Unknown

[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib

Colorectal Cancer

Korea, Republic of

Search clinical trials for: Regorafenib (Stivarga, BAY 73-4506)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations